[123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
Identifieur interne : 004E16 ( Ncbi/Checkpoint ); précédent : 004E15; suivant : 004E17[123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
Auteurs : J. Schwarz [Allemagne] ; K. Tatsch ; T. Gasser ; G. Arnold ; W H OertelSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1997.
English descriptors
- KwdEn :
- Adult, Aged, Apomorphine (diagnostic use), Apomorphine (metabolism), Atrophy (pathology), Benzamides (pharmacokinetics), Binding Sites, Cerebral Cortex (pathology), Dopamine (metabolism), Dopamine Agonists (metabolism), Dopamine Agonists (therapeutic use), Dopamine Antagonists (pharmacokinetics), Follow-Up Studies, Humans, Levodopa (therapeutic use), Magnetic Resonance Imaging, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (pathology), Parkinson Disease (radionuclide imaging), Predictive Value of Tests, Putamen (pathology), Pyrrolidines (pharmacokinetics), Receptors, Dopamine D2 (drug effects), Tomography, Emission-Computed, Single-Photon.
- MESH :
- chemical , diagnostic use : Apomorphine.
- chemical , drug effects : Receptors, Dopamine D2.
- chemical , metabolism : Apomorphine, Dopamine, Dopamine Agonists.
- drug therapy : Parkinson Disease.
- pathology : Atrophy, Cerebral Cortex, Parkinson Disease, Putamen.
- chemical , pharmacokinetics : Benzamides, Dopamine Antagonists, Pyrrolidines.
- radionuclide imaging : Parkinson Disease.
- chemical , therapeutic use : Dopamine Agonists, Levodopa.
- Adult, Aged, Binding Sites, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Middle Aged, Predictive Value of Tests, Tomography, Emission-Computed, Single-Photon.
Abstract
We investigated the cases of 55 patients with parkinsonism and prior dopaminomimetic therapy in whom the response to this treatment was questionable or reported to be negative. None of these patients had shown motor fluctuations prior to this study. We compared the results of imaging of dopamine-D2 receptors by using [123I]iodobenzamide-single-photon-emission computed tomography (IBZM-SPECT) with the improvement in motor signs following a subcutaneous injection of apomorphine and a subsequent increase in oral dopaminomimetic therapy. IBZM-SPECT accurately predicted a positive or negative response to apomorphine in 37 (84%) of 44 patients. The sensitivity/specificity was calculated as 96.3%/ 64.7%. The sensitivity/specificity of IBZM-SPECT for the response to oral treatment with levodopa (L-dopa) was calculated as 100%/75%. After a follow-up period of 2-4 years, 25 patients developed motor fluctuations. All of these patients had normal IBZM binding. Nine developed clinical signs indicating a basal ganglia disorder other than Parkinson's disease. Eight of these nine patients had reduced, and one patient had normal, IBZM binding. We conclude that normal IBZM binding is a useful predictor of a good response to dopaminergic drugs in patients with parkinsonism and a questionable response to previous dopaminomimetic therapy. Reduced IBZM binding seems to exclude a diagnosis of Parkinson's disease, because none of the latter patients clearly benefited from L-dopa and 66.7% developed clinical signs indicating another disorder of the basal ganglia.
DOI: 10.1002/mds.870120610
PubMed: 9399212
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004569
- to stream PubMed, to step Curation: 004569
- to stream PubMed, to step Checkpoint: 004525
- to stream Ncbi, to step Merge: 004E16
- to stream Ncbi, to step Curation: 004E16
Links to Exploration step
pubmed:9399212Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.</title><author><name sortKey="Schwarz, J" sort="Schwarz, J" uniqKey="Schwarz J" first="J" last="Schwarz">J. Schwarz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilian University, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilian University</wicri:regionArea><wicri:noRegion>Ludwig-Maximilian University</wicri:noRegion><wicri:noRegion>Ludwig-Maximilian University</wicri:noRegion><wicri:noRegion>Ludwig-Maximilian University</wicri:noRegion></affiliation></author><author><name sortKey="Tatsch, K" sort="Tatsch, K" uniqKey="Tatsch K" first="K" last="Tatsch">K. Tatsch</name></author><author><name sortKey="Gasser, T" sort="Gasser, T" uniqKey="Gasser T" first="T" last="Gasser">T. Gasser</name></author><author><name sortKey="Arnold, G" sort="Arnold, G" uniqKey="Arnold G" first="G" last="Arnold">G. Arnold</name></author><author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9399212</idno><idno type="pmid">9399212</idno><idno type="doi">10.1002/mds.870120610</idno><idno type="wicri:Area/PubMed/Corpus">004569</idno><idno type="wicri:Area/PubMed/Curation">004569</idno><idno type="wicri:Area/PubMed/Checkpoint">004525</idno><idno type="wicri:Area/Ncbi/Merge">004E16</idno><idno type="wicri:Area/Ncbi/Curation">004E16</idno><idno type="wicri:Area/Ncbi/Checkpoint">004E16</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.</title><author><name sortKey="Schwarz, J" sort="Schwarz, J" uniqKey="Schwarz J" first="J" last="Schwarz">J. Schwarz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilian University, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilian University</wicri:regionArea><wicri:noRegion>Ludwig-Maximilian University</wicri:noRegion><wicri:noRegion>Ludwig-Maximilian University</wicri:noRegion><wicri:noRegion>Ludwig-Maximilian University</wicri:noRegion></affiliation></author><author><name sortKey="Tatsch, K" sort="Tatsch, K" uniqKey="Tatsch K" first="K" last="Tatsch">K. Tatsch</name></author><author><name sortKey="Gasser, T" sort="Gasser, T" uniqKey="Gasser T" first="T" last="Gasser">T. Gasser</name></author><author><name sortKey="Arnold, G" sort="Arnold, G" uniqKey="Arnold G" first="G" last="Arnold">G. Arnold</name></author><author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Apomorphine (diagnostic use)</term><term>Apomorphine (metabolism)</term><term>Atrophy (pathology)</term><term>Benzamides (pharmacokinetics)</term><term>Binding Sites</term><term>Cerebral Cortex (pathology)</term><term>Dopamine (metabolism)</term><term>Dopamine Agonists (metabolism)</term><term>Dopamine Agonists (therapeutic use)</term><term>Dopamine Antagonists (pharmacokinetics)</term><term>Follow-Up Studies</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Magnetic Resonance Imaging</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (pathology)</term><term>Parkinson Disease (radionuclide imaging)</term><term>Predictive Value of Tests</term><term>Putamen (pathology)</term><term>Pyrrolidines (pharmacokinetics)</term><term>Receptors, Dopamine D2 (drug effects)</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Apomorphine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Apomorphine</term><term>Dopamine</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Atrophy</term><term>Cerebral Cortex</term><term>Parkinson Disease</term><term>Putamen</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Benzamides</term><term>Dopamine Antagonists</term><term>Pyrrolidines</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Binding Sites</term><term>Follow-Up Studies</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Middle Aged</term><term>Predictive Value of Tests</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We investigated the cases of 55 patients with parkinsonism and prior dopaminomimetic therapy in whom the response to this treatment was questionable or reported to be negative. None of these patients had shown motor fluctuations prior to this study. We compared the results of imaging of dopamine-D2 receptors by using [123I]iodobenzamide-single-photon-emission computed tomography (IBZM-SPECT) with the improvement in motor signs following a subcutaneous injection of apomorphine and a subsequent increase in oral dopaminomimetic therapy. IBZM-SPECT accurately predicted a positive or negative response to apomorphine in 37 (84%) of 44 patients. The sensitivity/specificity was calculated as 96.3%/ 64.7%. The sensitivity/specificity of IBZM-SPECT for the response to oral treatment with levodopa (L-dopa) was calculated as 100%/75%. After a follow-up period of 2-4 years, 25 patients developed motor fluctuations. All of these patients had normal IBZM binding. Nine developed clinical signs indicating a basal ganglia disorder other than Parkinson's disease. Eight of these nine patients had reduced, and one patient had normal, IBZM binding. We conclude that normal IBZM binding is a useful predictor of a good response to dopaminergic drugs in patients with parkinsonism and a questionable response to previous dopaminomimetic therapy. Reduced IBZM binding seems to exclude a diagnosis of Parkinson's disease, because none of the latter patients clearly benefited from L-dopa and 66.7% developed clinical signs indicating another disorder of the basal ganglia.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country></list><tree><noCountry><name sortKey="Arnold, G" sort="Arnold, G" uniqKey="Arnold G" first="G" last="Arnold">G. Arnold</name><name sortKey="Gasser, T" sort="Gasser, T" uniqKey="Gasser T" first="T" last="Gasser">T. Gasser</name><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name><name sortKey="Tatsch, K" sort="Tatsch, K" uniqKey="Tatsch K" first="K" last="Tatsch">K. Tatsch</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Schwarz, J" sort="Schwarz, J" uniqKey="Schwarz J" first="J" last="Schwarz">J. Schwarz</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E16 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 004E16 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:9399212
|texte= [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:9399212" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |